We don't just build software. We build drugs.
We are actively acquiring clinical-stage assets to run through our engine.
SIMULATION: FIB-001 [Oncology]
Comparative Velocity Analysis
The Math Behind the Magic
Our thesis is simple: the bottleneck in drug development isn't science—it's operations. Here's the data.
TIMELINE COMPRESSION ANALYSIS
Phase-by-Phase Breakdown: Discovery to IND
EROOM'S LAW
Drugs Approved per $1B R&D Spend (Indexed)
By automating the operational complexity that drives Eroom's Law—regulatory navigation, protocol optimization, and CMC documentation—we can reverse the productivity decline without changing the underlying science.
We Are Buying.
The industry is full of "dead" assets that aren't actually failures—they just failed to fit a timeline or a budget. We are looking for validated biology that needs a new operating system.
If you have an asset gathering dust because the Phase 2 protocol is "too complex" or the regulatory path is "too murky," we want it.
Contact Business DevelopmentACQUISITION_TARGETS
Clinical Stage
Phase 1 ready or Phase 2 stalled. We accelerate, we don't discover.
Data Rich
Must have solid preclinical packages. Our agents run on data, not hope.
Operational Bottlenecks
We seek assets where the primary blocker is execution speed or regulatory complexity.